ADMA Biologics Refutes Culper Research Short-Seller Allegations

ADMA Biologics has issued a formal statement strongly refuting the recent allegations made by short-seller firm Culper Research. The company characterized the report's claims as unsubstantiated and misleading, suggesting they were intended to manipulate the stock price. ADMA clarified that Culper Research fundamentally misunderstood the competitive market position of its key therapy, ASCENIV. Furthermore, the company reaffirmed its critical role in providing essential treatments for immune-compromised patients. This rebuttal aims to defend ADMA's business model and address the volatility typically triggered by short-seller reports in the biotech sector. While the conflict creates near-term uncertainty, the company remains focused on its operational goals and market leadership.

Sources:globenewswire.comstockstotrade.comtradingview.comstreetinsider.commarketscreener.comtipranks.comstocktitan.netprnewswire.combfalaw.combusinesswire.comholzerlaw.comnewsfilecorp.comglobenewswire.com